Keith M. Kerr
#136,335
Most Influential Person Now
Keith M. Kerr's AcademicInfluence.com Rankings
Keith M. Kerrphilosophy Degrees
Philosophy
#6899
World Rank
#10017
Historical Rank
Logic
#3991
World Rank
#5230
Historical Rank

Download Badge
Philosophy
Keith M. Kerr's Degrees
- Doctorate Medicine University of California, San Francisco
- PhD Biomedical Sciences University of California, San Francisco
Why Is Keith M. Kerr Influential?
(Suggest an Edit or Addition)Keith M. Kerr's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma (2011) (3193)
- The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification. (2015) (2865)
- Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2010) (1839)
- Tracking the Evolution of Non‐Small‐Cell Lung Cancer (2017) (1525)
- Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2017) (1102)
- Phylogenetic ctDNA analysis depicts early stage lung cancer evolution (2017) (1092)
- PD‐L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD‐L1 IHC Assay Comparison Project (2017) (1038)
- Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution (2017) (772)
- Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2017) (706)
- Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2012) (671)
- Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology (2018) (669)
- Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2012) (628)
- Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018) (626)
- Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2017) (616)
- PD‐L1 Immunohistochemistry Comparability Study in Real‐Life Clinical Samples: Results of Blueprint Phase 2 Project (2018) (525)
- Guidelines on the radical management of patients with lung cancer (2010) (485)
- Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies (2018) (376)
- Diagnosis of lung cancer in small biopsies and cytology: implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification. (2013) (368)
- PD-L1 as a biomarker of response to immune-checkpoint inhibitors (2021) (364)
- Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018) (355)
- Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2017) (336)
- Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC (2019) (298)
- Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. (2018) (294)
- Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors (2017) (292)
- Consensus for EGFR Mutation Testing in Non-small Cell Lung Cancer: Results from a European Workshop (2010) (289)
- Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non-Small-Cell Lung Cancer. (2017) (287)
- Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. (2022) (276)
- Evolving concepts in the pathology and computed tomography imaging of lung adenocarcinoma and bronchioloalveolar carcinoma. (2005) (263)
- UK Lung Cancer RCT Pilot Screening Trial: baseline findings from the screening arm provide evidence for the potential implementation of lung cancer screening (2015) (250)
- Programmed Death-Ligand 1 Immunohistochemistry in Lung Cancer: In what state is this art? (2015) (244)
- The challenge of NSCLC diagnosis and predictive analysis on small samples. Practical approach of a working group. (2012) (218)
- Subtyping of Undifferentiated Non-small Cell Carcinomas in Bronchial Biopsy Specimens (2010) (218)
- Pulmonary preinvasive neoplasia (2001) (215)
- EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations (2012) (211)
- Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer. (2014) (209)
- Tracking Genomic Cancer Evolution for Precision Medicine: The Lung TRACERx Study (2014) (208)
- Inter-observer variation between pathologists in diffuse parenchymal lung disease (2004) (204)
- Reproducibility of histopathological subtypes and invasion in pulmonary adenocarcinoma. An international interobserver study (2012) (196)
- Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2015) (191)
- Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. (2018) (182)
- Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung Cancer. (2019) (182)
- Testing for ROS1 in non-small cell lung cancer: a review with recommendations (2016) (181)
- The UK Lung Cancer Screening Trial: a pilot randomised controlled trial of low-dose computed tomography screening for the early detection of lung cancer. (2016) (178)
- The 2021 WHO Classification of Lung Tumors: Impact of advances since 2015. (2021) (177)
- Thyroid transcription factor 1 in pulmonary adenocarcinoma (2004) (174)
- Prevalence and clinical outcomes for patients with ALK-positive resected stage I to III adenocarcinoma: results from the European Thoracic Oncology Platform Lungscape Project. (2014) (168)
- Corrections to "Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018) (166)
- PD-L1 Testing for Lung Cancer in 2019: Perspective from the IASLC Pathology Committee. (2019) (163)
- Diagnosis of lung adenocarcinoma in resected specimens: implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification. (2013) (150)
- Diagnostic procedures for non-small-cell lung cancer (NSCLC): recommendations of the European Expert Group (2015) (149)
- Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: analysis of data from the EXTREME and CRYSTAL studies. (2013) (146)
- Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018) (145)
- EGFR Mutation Testing Practices within the Asia Pacific Region (2015) (143)
- Preoperative histological classification of primary lung cancer: accuracy of diagnosis and use of the non-small cell category (2000) (142)
- Geospatial immune variability illuminates differential evolution of lung adenocarcinoma (2020) (141)
- Bronchioloalveolar Carcinoma and Lung Adenocarcinoma: The Clinical Importance and Research Relevance of the 2004 World Health Organization Pathologic Criteria (2006) (140)
- Correction to: "Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up". (2019) (138)
- British Thoracic Society Guideline for the investigation and management of malignant pleural mesothelioma (2018) (137)
- Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2019) (133)
- IASLC MULTIDISCIPLINARY RECOMMENDATIONS FOR PATHOLOGIC ASSESSMENT OF LUNG CANCER RESECTION SPECIMENS FOLLOWING NEOADJUVANT THERAPY. (2020) (132)
- Gene Expression Profiling in Non-Small Cell Lung Cancer (2004) (132)
- Immune cell infiltrates and prognosis in primary carcinoma of the lung. (2000) (129)
- Pulmonary adenocarcinomas: classification and reporting (2009) (127)
- Pulmonary venous circulating tumor cell dissemination before tumor resection and disease relapse (2019) (119)
- Programmed Death Ligand-1 Immunohistochemistry: Friend or Foe? (2016) (116)
- The association between atypical adenomatous hyperplasia and primary lung cancer (2000) (111)
- The UK Lung Screen (UKLS): Demographic Profile of First 88,897 Approaches Provides Recommendations for Population Screening (2014) (111)
- Spatial heterogeneity of the T cell receptor repertoire reflects the mutational landscape in lung cancer (2019) (110)
- Interplay between whole-genome doubling and the accumulation of deleterious alterations in cancer evolution (2020) (109)
- Programmed Death Ligand-1 Immunohistochemistry--A New Challenge for Pathologists: A Perspective From Members of the Pulmonary Pathology Society. (2016) (105)
- Neuroendocrine differentiation in non‐small cell lung cancer and its relation to prognosis and therapy (2005) (104)
- The new IASLC/ATS/ERS international multidisciplinary lung adenocarcinoma classification (2009) (104)
- DNA Methylation Changes in Atypical Adenomatous Hyperplasia, Adenocarcinoma In Situ, and Lung Adenocarcinoma (2011) (102)
- The Use of Immunohistochemistry Improves the Diagnosis of Small Cell Lung Cancer and Its Differential Diagnosis. An International Reproducibility Study in a Demanding Set of Cases (2017) (100)
- The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee (2020) (97)
- THE PATTERN OF K‐rasMUTATION IN PULMONARY ADENOCARCINOMA DEFINES A NEW PATHWAY OF TUMOUR DEVELOPMENT IN THE HUMAN LUNG (1997) (96)
- Personalized medicine for lung cancer: new challenges for pathology (2012) (95)
- PD-1 blockade in advanced NSCLC: A focus on pembrolizumab. (2018) (94)
- Actual growth rate and tumour cell proliferation in human pulmonary neoplasms. (1984) (94)
- Merkel cell and squamous cell carcinomas arising in erythema ab igne (1993) (92)
- Causes of pulmonary granulomas: a retrospective study of 500 cases from seven countries (2011) (92)
- Biomarker Testing in Lung Carcinoma Cytology Specimens: A Perspective From Members of the Pulmonary Pathology Society. (2016) (92)
- Non-Small Cell Lung Cancer, PD-L1, and the Pathologist. (2016) (87)
- The International Association for the Study of Lung Cancer (IASLC) Global Survey on Molecular Testing in Lung Cancer. (2019) (87)
- Atypical alveolar hyperplasia: Relationship with pulmonary adenocarcinoma, p53, and c‐erbB‐2 expression (1994) (85)
- Quantitative Analysis of Tumor in Bronchial Biopsy Specimens (2010) (85)
- PD‐L1 testing for lung cancer in the UK: recognizing the challenges for implementation (2016) (82)
- A Grading system for invasive pulmonary adenocarcinoma: a proposal from the IASLC pathology committee. (2020) (78)
- The Role of DNA Methylation in the Development and Progression of Lung Adenocarcinoma (2007) (75)
- Surgical outcomes from the phase 3 CheckMate 816 trial: Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo alone as neoadjuvant treatment for patients with resectable non-small cell lung cancer (NSCLC). (2021) (74)
- Multicenter Immunohistochemical ALK-Testing of Non–Small-Cell Lung Cancer Shows High Concordance after Harmonization of Techniques and Interpretation Criteria (2014) (72)
- Interobserver variation in the classification of thymic tumours – a multicentre study using the WHO classification system (2008) (71)
- Screening for ALK in non-small cell lung carcinomas: 5A4 and D5F3 antibodies perform equally well, but combined use with FISH is recommended. (2015) (70)
- Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer. (2014) (70)
- A Grading System for Invasive Pulmonary Adenocarcinoma: A Proposal From the International Association for the Study of Lung Cancer Pathology Committee (2020) (69)
- Tumor Mutation Burden: Promises and Challenges A Perspective from the IASLC Pathology Committee. (2020) (68)
- Evaluation of NGS and RT‐PCR Methods for ALK Rearrangement in European NSCLC Patients: Results from the European Thoracic Oncology Platform Lungscape Project (2017) (66)
- Evaluation of NGS and RT‐PCR Methods for ALK Rearrangement in European NSCLC Patients: Results from the European Thoracic Oncology Platform Lungscape Project (2017) (66)
- Expression of matrix metalloproteinases 1, 2, 9 and their tissue inhibitors in stage II non-small cell lung cancer: implications for MMP inhibition therapy. (2001) (64)
- The evolving landscape of biomarker testing for non-small cell lung cancer in Europe. (2021) (64)
- Expression of bcl-2 and p53 in Merkel cell carcinoma. An immunohistochemical study. (1996) (64)
- Pathological assessment of mediastinal lymph nodes in lung cancer: implications for non-invasive mediastinal staging. (1992) (63)
- Partial regression in primary carcinoma of the lung: does it occur? (1998) (62)
- Control of infectious synovitis. 12. Preparation of an agglutination test antigen. (1963) (61)
- Thymidylate Synthase Expression and Outcome of Patients Receiving Pemetrexed for Advanced Nonsquamous Non–Small-Cell Lung Cancer in a Prospective Blinded Assessment Phase II Clinical Trial (2013) (61)
- The T cell differentiation landscape is shaped by tumour mutations in lung cancer (2020) (59)
- A clonal expression biomarker associates with lung cancer mortality (2019) (59)
- New Insights on Diagnostic Reproducibility of Biphasic Mesotheliomas: A Multi‐Institutional Evaluation by the International Mesothelioma Panel From the MESOPATH Reference Center (2018) (58)
- Precision medicine in NSCLC and pathology: how does ALK fit in the pathway? (2016) (58)
- Liquid Biopsy in Lung Cancer: A Perspective From Members of the Pulmonary Pathology Society. (2016) (56)
- Tumor transcriptome reveals the predictive and prognostic impact of lysosomal protease inhibitors in non-small-cell lung cancer. (2006) (55)
- Relationship Between EGFR Expression, EGFR Mutation Status, and the Efficacy of Chemotherapy Plus Cetuximab in FLEX Study Patients with Advanced Non–Small-Cell Lung Cancer (2014) (54)
- BAI3, CDX2 and VIL1: a panel of three antibodies to distinguish small cell from large cell neuroendocrine lung carcinomas (2014) (50)
- CONTROL OF INFECTIOUS SYNOVITIS 13. THE ANTIGEN STUDY OF (1964) (49)
- Abstract CT003: Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo as neoadjuvant treatment (tx) for resectable (IB-IIIA) non-small cell lung cancer (NSCLC) in the phase 3 CheckMate 816 trial (2021) (49)
- CT screening for lung cancer in the UK: position statement by UKLS investigators following the NLST report (2011) (47)
- HBME-1 and antithrombomodulin in the differential diagnosis of malignant mesothelioma of pleura. (1997) (47)
- Personalized cancer medicine and the future of pathology (2011) (45)
- Alveolar atypical hyperplasia in association with primary pulmonary adenocarcinoma: a clinicopathological study of 10 cases. (1992) (45)
- The deubiquitinating enzyme USP17 is associated with nonsmall cell lung cancer (NSCLC) recurrence and metastasis (2013) (45)
- Lung cancer mortality reduction by LDCT screening: UKLS randomised trial results and international meta-analysis (2021) (45)
- Necrotizing sarcoid granulomatosis with extrapulmonary involvement. (1997) (45)
- Prevalence and clinical association of MET gene overexpression and amplification in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape project. (2017) (42)
- Assessing standardization of molecular testing for non-small-cell lung cancer: results of a worldwide external quality assessment (EQA) scheme for EGFR mutation testing (2014) (41)
- Genomic instability at the BUB1 locus in colorectal cancer, but not in non-small cell lung cancer. (2000) (40)
- Expression of CD44v6 but not E‐cadherin or β‐catenin influences prognosis in primary pulmonary adenocarcinoma (2000) (40)
- Changing trends in incidence of lung cancer by histologic type in Scotland (2002) (39)
- Expression of Fhit, cell adhesion molecules and matrix metalloproteinases in atypical adenomatous hyperplasia and pulmonary adenocarcinoma (2004) (39)
- The role of the molecular footprint of EGFR in tailoring treatment decisions in NSCLC (2011) (39)
- Revolution in lung cancer: new challenges for the surgical pathologist. (2011) (38)
- Immune Checkpoint Blockade: A New Era for Non-Small Cell Lung Cancer (2016) (37)
- Hypersensitivity Pneumonitis A Perspective From Members of the Pulmonary Pathology Society. (2018) (36)
- Killing of Aspergillus fumigatus spores by human lung macrophages: a paradoxical effect of heat-labile serum components. (1989) (36)
- Evaluation of NQO1 gene expression and variant allele in human NSCLC tumors and matched normal lung tissue. (2002) (36)
- An audit of the clinical investigation of pleural effusion. (1992) (36)
- Lymphohistiocytoid Variant of Malignant Mesothelioma of the Pleura: A Series of 22 Cases (2007) (36)
- Metastatic pulmonary ameloblastoma. An unusual case. (2003) (36)
- Iron lung: bronchoscopic and pathological consequences of aspiration of ferrous sulphate. (1991) (35)
- ALK Immunohistochemistry in NSCLC: Discordant Staining Can Impact Patient Treatment Regimen (2016) (35)
- PARP inhibition induces BAX/BAK‐independent synthetic lethality of BRCA1‐deficient non‐small cell lung cancer (2011) (35)
- Cytology for PD-L1 testing: A systematic review. (2020) (34)
- Detection of anaplastic lymphoma kinase (ALK) gene rearrangement in non-small cell lung cancer and related issues in ALK inhibitor therapy: a literature review. (2012) (33)
- A retrospective cohort study of PD-L1 prevalence, molecular associations and clinical outcomes in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape Project. (2019) (33)
- Transbronchial Lung Cryobiopsy for Interstitial Lung Disease Diagnosis: A Perspective From Members of the Pulmonary Pathology Society. (2016) (33)
- Comprehensive molecular and pathological evaluation of transitional mesothelioma assisted by deep learning approach: a multi institutional study of the International Mesothelioma Panel from MESOPATH Reference Center. (2020) (32)
- BTS guideline for the investigation and management of malignant pleural mesothelioma (2018) (32)
- Lungscape: Resected Non–Small-Cell Lung Cancer Outcome by Clinical and Pathological Parameters (2014) (30)
- PL 03.03 Blueprint 2: PD-L1 Immunohistochemistry Comparability Study in Real-Life, Clinical Samples (2017) (30)
- Prevalence and Clinical Outcomes for Patients With ALK Gene Rearrangement in Europe: Preliminary Results from the European Thoracic Oncology Platform Lungscape Project (2012) (30)
- Reproducibility of immunohistochemical scoring for epidermal growth factor receptor expression in non-small cell lung cancer: round robin test. (2013) (30)
- Notification of tuberculosis: can the pathologist help? (1988) (30)
- Is bronchoscopic lung biopsy helpful in the management of patients with diffuse lung disease? (2007) (28)
- p53, c-erbB-2 and nm23 expression have no prognostic significance in primary pulmonary adenocarcinoma. (1997) (28)
- Accelerated silicosis in Scottish stonemasons (1991) (28)
- The Relevance of External Quality Assessment for Molecular Testing for ALK Positive Non-Small Cell Lung Cancer: Results from Two Pilot Rounds Show Room for Optimization (2014) (26)
- Programmed death-ligand 1 expression influenced by tissue sample size. Scoring based on tissue microarrays’ and cross-validation with resections, in patients with, stage I–III, non-small cell lung carcinoma of the European Thoracic Oncology Platform Lungscape cohort (2019) (26)
- Interobserver Variation among Pathologists and Refinement of Criteria in Distinguishing Separate Primary Tumors from Intrapulmonary Metastases in Lung (2017) (26)
- Reproducibility of Histopathological Diagnosis in Poorly Differentiated NSCLC: An International Multiobserver Study (2014) (25)
- Prevalence and clinical association of gene mutations through multiplex mutation testing in patients with NSCLC: results from the ETOP Lungscape Project (2018) (24)
- Primary pulmonary osteosarcoma (2001) (23)
- Pleomorphic, spindle cell, and giant cell carcinoma (2015) (23)
- The PD-L1 Immunohistochemistry Biomarker: Two Steps Forward, One Step Back? (2018) (23)
- Correlation of ROS1 Immunohistochemistry With ROS1 Fusion Status Determined by Fluorescence In Situ Hybridization. (2020) (22)
- Pancoast syndrome: an unusual complication of pulmonary infection by Staphylococcus aureus. (1992) (21)
- Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration for PD-L1 Testing In Non-Small Cell Lung Cancer. (2020) (21)
- Clinical relevance of the new IASLC/ERS/ATS adenocarcinoma classification (2013) (21)
- Detection of Anaplastic Lymphoma Kinase (ALK) Gene Rearrangement in Non-Small Cell Lung Cancer and Related Issues in ALK Inhibitor Therapy (2012) (21)
- Alveolar proteinosis with hypersensitivity pneumonitis: A new clinical phenotype (2010) (21)
- Prognostic impact of KRAS G12C mutation in patients with NSCLC: results from the ETOP Lungscape Project. (2021) (20)
- Corrigendum: Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution (2017) (20)
- Pachydermodactyly: confused with JCA. (1992) (19)
- Using DNA sequencing data to quantify T cell fraction and therapy response (2021) (19)
- Endobronchial lipoma associated with lobar bronchiectasis. (1991) (19)
- Idiopathic pulmonary fibrosis: an update. (2006) (19)
- Programmed Death-Ligand 1 Immunohistochemistry Assay Comparison Studies in NSCLC: Characterization of the 73-10 Assay (2020) (18)
- In compressed lung tissue microscopic sections of adenocarcinoma in situ may mimic papillary adenocarcinoma. (2013) (17)
- P2.16-03 CheckMate 816: A Phase 3 Trial of Neoadjuvant Nivolumab Plus Ipilimumab or Chemotherapy vs Chemotherapy in Early-Stage NSCLC (2018) (17)
- In vitro thymidine labelling of human pulmonary neoplasms. (1983) (17)
- Survival from malignant mesothelioma: where are we now? (2015) (17)
- Navigating Diagnostic and Treatment Decisions in Non‐Small Cell Lung Cancer: Expert Commentary on the Multidisciplinary Team Approach (2020) (16)
- An investigation into the role of human papillomavirus in endobronchial papillary squamous tumours. (1990) (15)
- Tuberculosis of the trachea. (1987) (15)
- Molecular testing in stage I-III non-small cell lung cancer: Approaches and challenges. (2021) (15)
- Molecular and Immune Biomarker Testing in Squamous‐Cell Lung Cancer: Effect of Current and Future Therapies and Technologies (2018) (14)
- Cell proliferation, cell loss and expression of bcl-2 and p53 in human pulmonary neoplasms. (1997) (14)
- Cutaneous penile and perianal Crohn's disease treated with a combination of medical and surgical interventions (2008) (14)
- A local human Vδ1 T cell population is associated with survival in nonsmall-cell lung cancer (2022) (14)
- EU–USA pathology panel for uniform diagnosis in randomised controlled trials for HRCT screening in lung cancer (2006) (13)
- Non-interventional LUME-BioNIS study of nintedanib plus docetaxel after chemotherapy in adenocarcinoma non-small cell lung cancer: A subgroup analysis in patients with prior immunotherapy. (2020) (13)
- EORTC-ETOP randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab versus placebo for patients with early stage non-small cell lung cancer (NSCLC) after resection and standard adjuvant chemotherapy: PEARLS (NCT02504372). (2016) (13)
- Identifying the Steps Required to Effectively Implement Next-Generation Sequencing in Oncology at a National Level in Europe (2022) (13)
- How to investigate a patient with suspected interstitial lung disease (2010) (12)
- A comparison of patient survival and tumour growth kinetics in human bronchogenic carcinoma. (1988) (12)
- Inter-observer Reliability of Programmed Cell Death Ligand-1 Scoring Using the VENTANA PD-L1 (SP263) Assay in Non-Small Cell Lung Cancer. (2019) (12)
- Bringing Greater Accuracy to Europe’s Healthcare Systems: The Unexploited Potential of Biomarker Testing in Oncology (2020) (12)
- Checkmate 816: A phase 3, randomized, open-label trial of nivolumab plus ipilimumab vs platinum-doublet chemotherapy as neoadjuvant treatment for early-stage NSCLC. (2017) (12)
- A noninterventional, multinational study to assess PD‐L1 expression in cytological and histological lung cancer specimens (2020) (12)
- Inflammatory endobronchial polyposis with bronchiectasis in cystic fibrosis. (2001) (11)
- A rare cause of recurrent massive pericardial and pleural effusions. (2008) (11)
- The impact on the multidisciplinary team of molecular profiling for personalized therapy in non-small cell lung cancer. (2013) (10)
- Morphology and genetics of pre-invasive pulmonary disease (2004) (10)
- Squamous cell carcinoma of an ileo‐anal pouch (2010) (10)
- Individualised treatment in non-small cell lung cancer: precise tissue diagnosis for all? (2011) (10)
- Design, construction, and analysis of cell line arrays and tissue microarrays for gene expression analysis. (2011) (10)
- Molecular pathology of lung cancer (2012) (10)
- Meta-analysis of the predictive and prognostic value of erlotinib-related biomarkers in phase III, placebo-controlled trials in non-small cell lung cancer (NSCLC): Recommendations of the BioLOGUE advisors. (2011) (10)
- Prognostic factors in resected lung carcinomas (2013) (10)
- ALK testing in non-small cell lung carcinoma: what now? (2014) (10)
- Defining aggressive or early progressing nononcogene-addicted non-small-cell lung cancer: a separate disease entity? (2019) (10)
- OA03.03 Phase 2B of Blueprint PD-L1 Immunohistochemistry Assay Comparability Study (2018) (9)
- RAPID SPECIFIC AGGLUTINATION OF EATON AGENT (MYCOPLASMA PNEUMONIAE) (1964) (9)
- 2nd ESMO Consensus Conference on Lung Cancer : non-small-cell lung cancer first-line/second and further lines in advanced disease (2014) (9)
- Diagnosis and predictive molecular analysis of non-small-cell lung cancer in the Africa-Middle East region: challenges and strategies for improvement. (2014) (9)
- Bringing Onco-Innovation to Europe’s Healthcare Systems: The Potential of Biomarker Testing, Real World Evidence, Tumour Agnostic Therapies to Empower Personalised Medicine (2020) (9)
- Classification of lung cancer: proposals for change? (2012) (8)
- Redefining Treatment Paradigms in First-line Advanced Non–Small-Cell Lung Cancer (2019) (8)
- Hydroxycarbamide‐induced pneumonitis (2009) (8)
- Pulmonary veno-occlusive disease complicating Felty's syndrome. (1998) (8)
- Association between Gene Expression Profiles and Clinical Outcome of Pemetrexed-Based Treatment in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer: Exploratory Results from a Phase II Study (2014) (8)
- The evolution of lung cancer and impact of subclonal selection in TRACERx (2023) (7)
- Serpin B3 Is Associated with Poor Survival after Chemotherapy and Is a Potential Novel Predictive Biomarker in Advanced Non–Small-Cell Lung Cancer (2013) (7)
- PD-L1 Immunohistochemistry Assay Comparison Studies in Non-Small Cell Lung Cancer: Characterization of the 73-10 Assay. (2020) (7)
- Clinical and molecular practice of European thoracic pathology laboratories during the COVID-19 pandemic. The past and the near future (2020) (7)
- Transbronchial and Endobronchial Biopsies (2008) (7)
- Spontaneous dissection of an anomalous systemic artery in the lung during pregnancy: a rare cause of hemoptysis. (2006) (7)
- Influence of tumour patterns in mixed-type adenocarcinoma on post-operative survival: P1-166 (2007) (7)
- Whole Transcriptome Analysis of Pre-invasive and Invasive Early Squamous Lung Carcinoma in Archival Laser Microdissected Samples (2017) (6)
- Novel active agents in patients with advanced NSCLC without driver mutations who have progressed after first-line chemotherapy (2016) (6)
- Genomic–transcriptomic evolution in lung cancer and metastasis (2023) (6)
- UK Lung Cancer RCT Pilot Screening Trial (2016) (6)
- Pathology and personalized medicine in lung cancer (2013) (6)
- The evolution of non-small cell lung cancer metastases in TRACERx (2023) (6)
- Mycobacterium microti infection associated with spindle cell pseudotumour and hypercalcaemia: a possible link with an infected alpaca (2010) (6)
- IASLC Global Survey on PD-L1 Testing for Non-Small Cell Lung Cancer. (2021) (6)
- Precision Molecular Pathology of Lung Cancer (2017) (6)
- Computer‐Based Intensity Measurement Assists Pathologists in Scoring Phosphatase and Tensin Homolog Immunohistochemistry — Clinical Associations in NSCLC Patients of the European Thoracic Oncology Platform Lungscape Cohort (2018) (6)
- Expert opinion on NSCLC small specimen biomarker testing — Part 1: Tissue collection and management (2022) (6)
- 66 UK Lung Cancer Screening trial (UKLS): Prevalence data at baseline (2014) (6)
- Calcified pulmonary chondromas in Carney's triad (2013) (6)
- O-39 Cell cycle marker MCM2 in peripheral lung adenocarcinoma and its precursors (2003) (5)
- Closed pleural biopsy to diagnose mesothelioma: dead or alive? (2009) (5)
- Pathologist and molecular biologist, ever the twain shall meet? (2009) (5)
- MA26.07 ROS1 (SP384) Immunohistochemistry Inter-Reader Precision Between 12 Pathologists (2018) (5)
- A comparison of cobalt (57Co) bleomycin scanning and contrast-enhanced CT scanning for assessment of the mediastinum in lung cancer. (1990) (5)
- Sarcoidosis (2009) (5)
- Predictive Biomarkers for Immunotherapy in Lung Cancer: Perspective from the IASLC Pathology Committee. (2022) (5)
- Large cell neuroendocrine lung carcinoma: consensus statement from The British Thoracic Oncology Group and the Association of Pulmonary Pathologists (2021) (5)
- UNITED KINGDOM LUNG CANCER SCREENING (UKLS) TRIAL (2011) (5)
- The differential diagnosis of pulmonary pre-invasive lesions (2007) (4)
- 9002 ORAL Round Robin Test to Evaluate the Reproducibility of a Therapeutically Relevant Immunohistochemical Score for the Categorization of Non-Small Cell Lung Cancer (NSCLC) Into Tumours With High and Low Epidermal Growth Factor Receptor (EGFR) Expression (2011) (4)
- Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA (2023) (4)
- Comparison of SP142 and 22C3 Immunohistochemistry PD-L1 Assays for Clinical Efficacy of Atezolizumab in Non-Small Cell Lung Cancer: Results From the Randomized OAK Trial. (2021) (4)
- The Classification of Pre-invasive Lesions (2012) (4)
- Non-oncogene addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up†. (2023) (4)
- Mixed Squamous Cell and Glandular Papilloma (2017) (4)
- Pathological and clinical investigation of pulmonary atypical adenomatous hyperplasia and its association with primary lung adenocarcinoma (2000) (3)
- Histological appearances of putative montelukast related Churg–Strauss syndrome (2008) (3)
- D4-05: Is survival after surgical resection of lung cancer influenced by the presence of atypical adenomatous hyperplasia (AAH)? (2007) (3)
- The International Association for the Study of Lung Cancer Global Survey on Programmed Death-Ligand 1 Testing for NSCLC (3)
- Relapsing necrotising sarcoid granulomatosis in a young patient (2007) (3)
- Publisher Correction: Pulmonary venous circulating tumor cell dissemination before tumor resection and disease relapse (2020) (3)
- Lung adenocarcinoma promotion by air pollutants (2023) (3)
- 39: Mutation analysis and association with TTF1 expression in lung non-squamous NSCLC (2015) (3)
- Antibodies against endogenous retroviruses promote lung cancer immunotherapy (2023) (3)
- Expert opinion on NSCLC small specimen biomarker testing — Part 2: Analysis, reporting, and quality assessment (2022) (3)
- Correlation between thymidylate synthetase (TS) expression and progression-free survival (PFS) in patients receiving pemetrexed (pem) for advanced NSCLC: A prospective study. (2012) (3)
- Nintedanib (N) + docetaxel (D) after immunotherapy in adenocarcinoma non-small cell lung cancer (NSCLC): First results from the non-interventional LUME-BioNIS study (2019) (3)
- Abstract 3631: United Kingdom lung cancer screening trial (UKLS): First 88897 approaches. (2013) (2)
- The European Thoracic Oncology Platform Lungscape project: Clinical outcome data as a basis for molecular correlations in resected non-small cell lung cancer. (2013) (2)
- Current issues in pulmonary adenocarcinoma (2008) (2)
- Penile metastases from carcinoma of the prostate. (1997) (2)
- Thymidylate synthetase (TS) immunohistochemistry (IHC): Feasibility in a routine clinical setting for patients receiving treatment with pemetrexed for advanced nonsquamous NSCLC. (2010) (2)
- 81 The uniqueness of the United Kingdom Lung Cancer Screening trial (UKLS) – a population screening study (2013) (2)
- Abstract CT012: Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo as neoadjuvant treatment for resectable (IB-IIIA) non-small cell lung cancer (NSCLC): Event-free survival (EFS) results from the phase 3 CheckMate 816 trial (2022) (2)
- Endobronchial ultrasound transbronchial needle aspiration at Aberdeen Royal Infirmary: the initial experience. (2012) (2)
- non-invasive mediastinal staging . lymph nodes in lung cancer : implications for Pathological assessment of mediastinal (2)
- The 2015 World Health Organisation Classification of Lung Cancer (2018) (2)
- Predictive Biomarkers for Immunotherapy in Lung Cancer: Perspective From the International Association for the Study of Lung Cancer Pathology Committee (2022) (2)
- P2.09-24 IASLC Global Survey for Pathologists on PD-L1 Testing for Non-Small Cell Lung Cancer (2019) (2)
- Prevalence and clinical association of MET gene amplification in patients with NSCLC: results from the ETOP lungscape project (2015) (2)
- Publisher Correction: Spatial heterogeneity of the T cell receptor repertoire reflects the mutational landscape in lung cancer (2020) (2)
- External Quality Assessment for ALK Immunohistochemistry Testing in Lung Adenocarcinoma Within the European Thoracic Oncology Platform Lungscape Project (2012) (2)
- Malignant pleural mesothelioma: ESMOClinical Practice Guidelines for diagnosis, treatment and follow-up† (2015) (2)
- Repair of iatrogenic distal tracheal rupture by left thoracotomy. (2007) (2)
- OLIGOMETASTATIC NON-SMALL CELL LUNG CANCER: A SIMULATION EXPERT MULTIDISCIPLINARY TUMOR BOARD (2013) (2)
- Pilot Screening Trial : baseline findings from the screening arm provide evidence for the potential implementation of lung cancer screening ' (2016) (1)
- Immunotherapy and Lung Cancer: Programmed Death 1 and Its Ligand as a Target for Therapy (2018) (1)
- 30 – Precursors of Malignancy (2017) (1)
- Pulmonary Pathology (2018) (1)
- Spencer's Pathology of the Lung: Pulmonary pre-invasive disease (2013) (1)
- Prevalence and clinical correlation of programmed cell death 1 ligand (PD-L1) expression in patients with resected non-small cell lung cancer (NSCLC): Results from the European Thoracic Oncology Platform (ETOP) Lungscape cohort. (2017) (1)
- Clinical recommendations for EGFR mutation testing in non-small cell lung cancer (NSCLC): Results from a European workshop. (2010) (1)
- Defining morphologic features of invasion in pulmonary non-mucinous adenocarcinoma with lepidic growth - A proposal by the IASLC Pathology Committee. (2022) (1)
- O-41 Expression of Fhit, cell adhesion molecules and matrix metalloproteinases in lung adenocarcinoma and its precursors (2003) (1)
- PP 56 Suitability of advanced non-small cell lung cancer biopsies for prospective, multiple molecular analyses in clinical trials (2011) (1)
- Responses of specific-pathogen-free chicks to concomitant infections of reovirus (WVU-2937) and infectious bursal disease virus. (1983) (1)
- A molecular profile that predicts response to platinum based chemotherapy in non-small cell lung cancer (NSCLC) patients (2004) (1)
- 1382TiPInvestigation of biomarkers in patients with adenocarcinoma of the lung receiving nintedanib according to approved label: Non-interventional LUME-BioNIS study (2017) (1)
- Evolutionary characterisation of lung adenocarcinoma morphology in TRACERx (2023) (1)
- 3001 Prevalence and clinical association of gene mutations through Multiplex Mutation Testing in patients with NSCLC: Results from the ETOP Lungscape Project (2015) (1)
- Precision Medicine in Lung Cancer (2018) (1)
- A rare cause of pleural disease. (2013) (1)
- Preneoplastic and Preinvasive Lesions (2008) (1)
- Molecular Testing in Lung Cancer Pathology (2014) (1)
- Histological diagnosis: recent developments (2015) (1)
- P3.01-021 Reproducibility of Comprehensive Histologic Assessment and Refining Histologic Criteria in P Staging of Multiple Tumor Nodules: Topic: Morphology (2017) (1)
- Results of a Pilot External Quality Assurance Scheme for Somatic EGFR Mutation Testing in Non-Small Cell Lung Cancer Managed by EMQN, ESMO, ESP, and ETOP (2011) (1)
- Bringing onco-innovation to Europe’s healthcare systems: the unexploited potential of biomarker testing, real world evidence and the potential of Tumour Agnostics. The lesson from BRCA1/2 genetic testing (2020) (0)
- Revised Classification for Adenocarcinoma (2012) (0)
- Update on large cell carcinomas of the lung (2014) (0)
- Inter-rater reliability of programmed death ligand 1 (PD-L1) scoring using the VENTANA PD-L1 (SP263) assay in non-small cell lung cancer (NSCLC). (2018) (0)
- Vindesine and etoposide chemotherapy in the management of patients with small cell lung cancer and poor prognosis. (1991) (0)
- Atypical Adenomatous Hyperplasia, Lung (2018) (0)
- Best practice in PD-L1 testing of non-small cell lung cancer in the UK: current problems and potential solutions (2021) (0)
- UK Lung Cancer Screening trial documentation (2016) (0)
- 33IN THE CONCEPT OF NEUROENDOCRINE TUMORS (2011) (0)
- 75: EGFR-mutant non-small cell lung cancer in Aberdeen, Scotland – Treatment and outcomes (2017) (0)
- Influence of CD44v6, E-cadherin and β-catenin expression on the behaviour of primary lung adenocarcinoma (2000) (0)
- United Kingom lung cancer screening (UKLS) trial [Conference abstract] (2011) (0)
- Characterization of Salmonella hadar (2013) (0)
- An unusual case of ALK mutation in large-cell neuroendocrine carcinoma of lung and response to alectinib (2021) (0)
- P-654 Large cell neuroendocrine lung carcinoma: Clinically more small than non-small? (2003) (0)
- MA 06.06 Assessment of RANK Prevalence and Clinical Significance in the NSCLC European Thoracic Oncology Platform Lungscape Cohort (2017) (0)
- Liquid Biopsy in Lung Cancer. (2016) (0)
- Computed tomography scan findings and the early outcome of patients referred to the multidisciplinary team (2016) (0)
- Evaluation of machine learning versus Cox regression in identification of factors predicting recurrence following resection of non-small cell lung cancer. (2010) (0)
- P1.02-025 Evaluation of NGS and RT-PCR Methods for ALK Assessment in European NSCLC Patients: Results from the ETOP Lungscape Project: Topic: Driver Genes in NSCLC, Resistance, and Other (2017) (0)
- 44 The first 100 endobronchial ultrasound transbronchial needle aspirations at Aberdeen Royal Infirmary (2012) (0)
- Mucoepidermoid Carcinoma, Lung (2017) (0)
- Wang ZZ . ' I ' racheobronchial tumors : an eighteen year series from Capital Hospital , Peking , China (0)
- O.04 Results from the IASLC Global Survey on Molecular Testing in Lung Cancer (2019) (0)
- 1199PDPREVALENCE AND CLINICAL OUTCOMES FOR PATIENTS WITH MET PROTEIN EXPRESSION IN PATIENTS WITH NON-SMALL CELL LUNG CANCER IN EUROPE: RESULTS FROM THE EUROPEAN THORACIC ONCOLOGY PLATFORM LUNGSCAPE PROJECT. (2014) (0)
- Molecular mechanisms of cytotoxicity and pathogenesis in non-small cell lung cancer (NSCLC) using gene expression profiling. (2003) (0)
- 18 NSCLC second line therapy with erlotinib: review of patients' outcomes (2011) (0)
- Authors' response. (2013) (0)
- Necrosis as a predictor of infection in granulomatous lung disease (2013) (0)
- Quality improvement in lung cancer: Aims and achievements in the North of Scotland (2010) (0)
- Interplay between whole-genome doubling and the accumulation of deleterious alterations in cancer evolution (2020) (0)
- Agreement Of Pathological Diagnosis In Fibrosing Interstitial Pneumonia (2010) (0)
- 7IN WHAT CAN BE ACHIEVED WITH PRESENT PATHOLOGY (2011) (0)
- Minute Meningothelial Nodules (2017) (0)
- Authors' response (2012) (0)
- Minimally Invasive Adenocarcinoma (MIA) (2017) (0)
- Lung Cancer RCT Pilot Screening Trial : baseline fi ndings from the screening arm provide evidence for the potential implementation of lung cancer screening (2016) (0)
- Adenocarcinoma In Situ (2018) (0)
- DNA Methylation Changes in Developing Lung Adenocarcinoma: P2-017 (2007) (0)
- 5IN ESMO NON-SMALL-CELL LUNG CANCER (NSCLC) CONSENSUS ON PATHOLOGY AND MOLECULAR TESTING (2011) (0)
- Biomarkers for the classification of highly malignant neuroendocrine lung carcinoma (2012) (0)
- Improving practice in PD-L1 testing of non-small cell lung cancer in the UK: current problems and potential solutions. (2023) (0)
- PP 15 BRCA1 expression is required for efficacy of vinorelbine and is a predictive biomarker in malignant mesothelioma (2011) (0)
- HBME-1andantithrombomodulin inthe differential diagnosis ofmalignant mesothelioma ofpleura (1997) (0)
- Mucous Gland Adenoma, Lung (2017) (0)
- OA01.09 Comparing Regional Results from the IASLC Global Survey on Molecular Testing in Lung Cancer (2019) (0)
- Publisher Correction: A clonal expression biomarker associates with lung cancer mortality (2020) (0)
- 7 Acquired resistance to TKIs in NSCLC; detection of low level T790M using an LNA clamp sequencing method (2014) (0)
- Lecce (12) found infectious-synovitis-derived pleuro- pneumonia-like organisms (ISD-PPLO) colonies growing as (2016) (0)
- The Lungscape Project. (2012) (0)
- P-679 EU-US pathologypanel for uniform diagnosis in randomised controlled trials for ct screening of lung cancer. Learning phase in diagnosis of early lung cancer (2005) (0)
- 25 Interobserver agreement in the evaluation of urine cytology for the detection of urothelial malignancy (2006) (0)
- P2.13-25 Analysis of EGFR Mutations Using Circulating Tumour DNA (ctDNA) in Non-Small Cell Lung Cancer Patients in North East Scotland (2018) (0)
- Details of the Liverpool Lung Project risk model (version 2) (2016) (0)
- 311 MAGEA tumour antigens mediate platinum cytotoxicity in NSCLC (2010) (0)
- Erlotinib use in NSCLC: how are we getting on? (2008) (0)
- Pronostic et cible de la therapie de cancer (2006) (0)
- Neoantigen-directed immune escape in lung cancer evolution (2019) (0)
- PUB015 The Use of Immunohistochemistry Improves the Diagnosis of SCLC. An International Reproducibility Study in a Demanding Set of Cases (2017) (0)
- 57 Squamous cell and adenocarcinoma ‘lineage’ markers in large cell carcinoma of the lung (2012) (0)
- 222 MesobanK – a UK based bioresource for malignant mesothelioma (2014) (0)
- Bronchioloalveolar Carcinoma/adenocarcinoma-in-situ (2012) (0)
- Computer-based intensity measurement assists pathologists in scoring PTEN immunohistochemistry - Clinical associations in NSCLC patients of the ETOP Lungscape cohort (2019) (0)
- 21 High sensitivity detection of epidermal growth factor receptor (EGFR) T790M mutants in non-small-cell lung cancer (2013) (0)
- Docetaxel first line use in advanced NSCLC (2008) (0)
- Clear Cell Tumor of Lung, Cytological Findings (2017) (0)
- Molecular Pathology of Precursor and Pre-invasive Lesions (2012) (0)
- Geospatial immune variability illuminates differential evolution of lung adenocarcinoma (2020) (0)
- Response. (2020) (0)
- Advances in Surgical Pathology: Lung Cancer (2012) (0)
- P2-289: Docetaxel with platinum as first line chemotherapy in advanced non-small cell lung cancer (NSCLC) (2007) (0)
- Abstract IA15: Bringing personalized therapy into the clinic: Can pathology deliver? (2012) (0)
- Radiological interventions and outcomes (2016) (0)
- 12 Current and ex-smokers with primary lung adenocarcinoma should be tested for EGFR mutation (2013) (0)
- Data tables showing demographics of response and recruitment (2016) (0)
- Authors' response (2011) (0)
- Plain language summary of the CheckMate 816 study results: nivolumab plus chemotherapy given before surgery for non-small-cell lung cancer. (2023) (0)
- Trial randomisation method (outlined in Chapter 2) (2016) (0)
- A Prospective Multicenter Study for ALK IHC plus Metastasized NSCLC (2015) (0)
- Relationship Between EGFR Expression Level, EGFR Mutation Status and the Efficacy of Chemotherapy Plus Cetuximab in Flex Study Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) (2012) (0)
- 139TiPA non-interventional biomarker study in patients (pts) with non-small cell lung cancer (NSCLC) of adenocarcinoma histology who are treated with nintedanib according to the approved label (LUME-BioNIS) (2017) (0)
- Significant decline in cancer diagnostic testing in U.S. CMS population during the COVID-19 pandemic. (2021) (0)
- Optimizing measurement of EGFR mutation status in NSCLC. (2010) (0)
- 1630PDAssociation of programmed cell death 1 ligand (PD-L1) expression with molecular alterations in non-small cell lung cancer (NSCLC) patients (pts): Results from the European Thoracic Oncology Platform (ETOP) Lungscape cohort (2017) (0)
- P-104 Identification of the lysosomal programmed cell death (PCD)pathway as a critical determinant of clinical response in Non-Small Cell Lung Cancer (NSCLC) (2005) (0)
- Proposed revisions to the classification of Adenocarcinoma (2012) (0)
- Endobronchial ultrasound transbronchial needle aspiration at Aberdeen Royal Infirmary: How are we doing? (2012) (0)
- Tuberculosis through the rose tinted spectacles of the EBUS endoscopist: be aware of the bias response (2012) (0)
- P3.04-009: Evaluation of RT-PCR Methodology for ALK Assessment in Patients with NSCLC in Europe: Results from the ETOP Lungscape Project (2015) (0)
- Publisher Correction: A clonal expression biomarker associates with lung cancer mortality (2020) (0)
- The pathology of screen-detected lesions (2006) (0)
- Recruitment of participants (2016) (0)
- An analysis of mRNA and long non-coding RNA (lncRNA) expression during the progression from pre-invasive lesions (PL) to invasive squamous cell carcinoma (SqCC) of the bronchus (2013) (0)
- Publisher Correction: Spatial heterogeneity of the T cell receptor repertoire reflects the mutational landscape in lung cancer (2020) (0)
- Hypoxia PET/CT and Colorectal Cancer: A Case Report (2020) (0)
- Summary report of UK Lung Cancer Screening sample quality control (2016) (0)
- 11 Second-line erlotinib in unselected NSCLC: audit of benefit (2011) (0)
- Results of the Second Pilot External Quality Assurance Scheme for Somatic Egfr Mutation Testing in Non-Small-Cell Lung Cancer (NSCLC) (2012) (0)
- ETOP activity in the field of biomarkers and predictors (2012) (0)
- Body composition and lung cancer-associated cachexia in TRACERx (2023) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Keith M. Kerr?
Keith M. Kerr is affiliated with the following schools: